This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 290035 results found since Jan 2013.

microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome
228;nström, C Larsson & W-O Lui
Source: British Journal of Cancer AOP - October 30, 2014 Category: Cancer & Oncology Authors: P AkçakayaS CaramutaJ ÅhlenM GhaderiE BerglundA ÖstmanR BränströmC LarssonW-O Lui Tags: microRNA PTPN18 miR-125a-5p gastrointestinal stromal tumours imatinib resistance sarcoma prognosis Source Type: research

Gastrointestinal stromal tumours: pathology and differential diagnosis
Abstract: Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumours in the digestive tract. Although the GIST diagnosis is facilitated by the existence of several very sensitive immunohistochemical markers the correct diagnosis may be missed due to several reasons: low or only focal expression of the most sensitive marker CD117 (KIT receptor), unusual morphology or uncommon location. Among the morphological subtypes are spindle, epithelioid and mixed cell phenotypes. Often, the phenotype can serve as a first indicator for the genotype and the expected biological behaviour. Immunohistochemistry can al...
Source: Diagnostic Histopathology - May 6, 2013 Category: Pathology Authors: Eva Wardelmann Tags: Mini-Symposium: Pathology of Gastrointestinal Stromal Tumours Source Type: research

Rationale and design of a UK database for a rare cancer type: the GEM Registry for gastrointestinal stromal tumours
J White & I Judson
Source: British Journal of Cancer AOP - August 20, 2013 Category: Cancer & Oncology Authors: V R BulusuJ FullartonM LeahyC MorganA RasheedP TaniereS TohM VerrillJ WhiteI Judson Tags: gastrointestinal stromal tumour GIST imatinib registry sunitinib tyrosine kinase inhibitor Source Type: research

Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?
Conclusion Upfront evaluation of kit mutation status may help us in delineating separate treatment strategies for potentially biologically different tumours and assessing the correct timing of surgery for this subset of GIST.
Source: Journal of Gastrointestinal Cancer - May 23, 2016 Category: Cancer & Oncology Source Type: research

Diagnostic and Therapeutic Challenges in the Management of Acute Massive Overt Bleeding of Jejunal Gastrointestinal Stromal Tumours: Case Series
ConclusionMultiphasic CTA is a single-step diagnostic tool for localisation of bleed and assessment of tumour characteristics in emergent conditions. Surgical resection is the mainstay of treatment for both control of bleed and to provide oncologically clear resection margins.
Source: Journal of Gastrointestinal Cancer - February 24, 2022 Category: Cancer & Oncology Source Type: research

Ki67 as a prognostic factor for long-term outcome following surgery in gastrointestinal stromal tumors
Conclusion: A high Ki67 expression seems to be a useful prognostic factor that would aid in predicting disease course in gastrointestinal stromal tumors. These findings deserve further investigation in larger studies.
Source: European Journal of Gastroenterology and Hepatology - September 30, 2015 Category: Gastroenterology Tags: Original Articles: Gastrointestinal Stromal Tumours Source Type: research

Resection Combined with TKI Therapy for Resectable Liver Metastases of Gastrointestinal Stromal Tumours: Results from Three National Centres in China
ConclusionsFor patients with resectable liver metastases, hepatic resection combined with TKI therapy was more beneficial in terms of improving prognosis than TKIs alone. In terms of the timing of TKI therapy and hepatic resection, resection combined with perioperative TKIs may prolong PFS more than resection combined with postoperative TKIs only.
Source: Journal of Gastrointestinal Surgery - June 10, 2019 Category: Surgery Source Type: research

Risk assessment and pathological reporting of gastrointestinal stromal tumour
Abstract: Gastrointestinal stromal tumour (GIST) is the most common mesenchymal neoplasm of the GI tract. GISTs form a biological continuum ranging from benign incidentally detected minute lesions (stromal tumourlets) of no clinical significance to large and highly malignant sarcomatous neoplasms. The disease is characterized by indistinct borders between biologically different subsets within its spectrum leading to unpredictable course of the disease in the majority of cases. Availability of effective tyrosine kinase inhibitors underlined the urgent need for a reliable risk assessment system to reliably identify those pat...
Source: Diagnostic Histopathology - May 14, 2013 Category: Pathology Authors: Abbas Agaimy Tags: Mini-Symposium: Pathology of Gastrointestinal Stromal Tumours Source Type: research

Minimally invasive experience for the treatment of gastrointestinal stromal tumours.
We report a case series of three pauci-sympomatic patients, all hospitalised for severe anaemia related to a chronic gastrointestinal bleeding, successfully treated by laparoscopic approach for the removal of gastrointestinal stromal tumours, two located in the stomach and one in the jejunum. KEY WORDS: Anaemia, Gastrointestinal stromal tumour (GIST), Laparoscopic approach, Jejunum, Stomach. PMID: 26344003 [PubMed - in process]
Source: Annali Italiani di Chirurgia - December 2, 2015 Category: Surgery Tags: Ann Ital Chir Source Type: research

Review article: the biology, diagnosis and management of gastrointestinal stromal tumours
ConclusionsGastrointestinal stromal tumours are rare tumours of the gastrointestinal tract and they vary in presentation. When surgical resection is not achievable, imatinib is the treatment of choice.
Source: Alimentary Pharmacology and Therapeutics - April 20, 2014 Category: Drugs & Pharmacology Authors: N. Iorio, R. A. Sawaya, F. K. Friedenberg Tags: Review Article Source Type: research

A novel surgical strategy for the resection of duodenal gastrointestinal stromal tumours located close to the duodenal ampulla: a case report.
Abstract Although the optimal surgical procedure for the resection of duodenal gastrointestinal stromal tumours has not yet been characterised due to the low prevalence of these tumours and the anatomical complexity of the duodenopancreatic region, difficult surgical procedures such as pancreaticoduodenectomy are often proposed for stromal tumours located in the second portion of the duodenum. Our case report highlights a novel surgical strategy that can be implemented as an alternative to pancreaticoduodenectomy for such tumours close to the duodenal ampulla. A 70-year-old man incidentally diagnosed with a stroma...
Source: Annals of the Royal College of Surgeons of England - September 10, 2019 Category: Surgery Authors: Kono S, Kumamoto T, Kurahashi Y, Niwa H, Ishida Y, Shinohara H Tags: Ann R Coll Surg Engl Source Type: research

Caveolin-1 expression predicts favourable outcome and correlates with PDGFRA mutations in gastrointestinal stromal tumours (GISTs)
Conclusion Caveolin-1 represents a novel prognostic marker in gastrointestinal stromal tumours. Further studies are warranted to validate these results and to explore the mechanisms linking Caveolin-1 expression with the PDGFRA oncogenic pathway.
Source: Journal of Clinical Pathology - November 17, 2022 Category: Pathology Authors: Bertero, L., Gambella, A., Barreca, A., Osella-Abate, S., Chiusa, L., Francia di Celle, P., Lista, P., Papotti, M., Cassoni, P. Tags: Original research Source Type: research

Cancers, Vol. 15, Pages 4081: Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours
litano Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract. Surgical treatment is recommended for the majority of localised GIST, while systemic treatment is the cornerstone of management for metastatic or unresectable disease. While a three-year regimen of imatinib is the standard of care in the adjuvant setting, there is no precise recommendation for the duration of neoadjuvant treatment, where imatinib is usually given between 4 and 12 months. Continuous treatment with imatinib at a dose of 400 mg once per day is recommended for most patients with unresectabl...
Source: Cancers - August 13, 2023 Category: Cancer & Oncology Authors: Marin Gol čić Robin L. Jones Paul Huang Andrea Napolitano Tags: Review Source Type: research

Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy
AbstractRipretinib (Qinlock®) is a small molecule inhibitor of the receptor tyrosine kinases KIT and platelet-derived growth factor receptor α (PDGFRA) and is approved for the treatment of gastrointestinal stromal tumours as a fourth-line of therapy. After successive cycles of treatment, gastrointestinal stromal tumours can carry a wide array of mutations, which makes resistance to treatment more likely. Ripretinib has a dual mechanism of action that allows it to target a broad spectrum of mutations in KIT or PDGFRA. The pivotal phase III INVICTUS trial demonstrated an increase of progression-free survival in patients re...
Source: Drugs - October 25, 2022 Category: Drugs & Pharmacology Source Type: research